参考文献/References:
[1]中华医学会糖尿病学分会.中国2型糖尿病防治指南(2017年版)[J].中华糖尿病杂志,2018,10(1):4-67. [2]American Diabetes Association.Standards of medical care in diabetes-2014[J].Diabetes Care,2014,37(1):S14-S80. [3]Haluzm M.Long-acting insulins in the treatment of type 2 diabetes and their position in the current treatment algorithm[J].Vnitr Lek,2017,63(2):87-92. [4]Fujita Y,Inagaki N.Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes:clinical data and mechanism of action[J].Journal of Diabetes Investigation,2014,5(3):265-275. [5]Di LL,Mangano M,Ronco C,et al.The treatment of type 2 diabetes mellitus in patients with chronic kidney disease:what to expect from new oral hypoglycemic agents[J].Diabetes Metab Syndr,2017,11(1):S295-S305. [6]Choi CI.Sodium-glucose cotransporter 2(SGLT2)inhibitors from natural products:discovery of next-generation antihyperglycemic agents[J].Molecules,2016,21(9):1136. [7]Tahrani AA,Barnett AH,Bailey CJ.SGLT inhibitors in management of diabetes[J].Lancet Diabetes Endocrinol,2013,1(2):140-151. [8]DeFronzo RA,Hompesch M,Kasichayanula S,et al.Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes[J].Diabetes Care,2013,36(10):3169-3176. [9]石卫峰,李晓宇,刘皋林.治疗2型糖尿病新药达格列净[J].中国新药杂志,2013,22(16):1861. [10]Yang L,Li H,Li H,et al.Pharmacokinetic and pharmacodynamic properties of single and multiple-dose of dapagliflozin,a selective inhibitor of SGLT2,in healthy Chinese subjects[J].Clin Ther,2013,35(8):1211-1222. [11]Garnock-Jones KP.Saxagliptin/Dapagliflozin:a review in type 2 diabetes mellitus[J].Drugs,2017,77(3):319-330. [12]Kaku K,Inoue S,Matsuoka O,et al.Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control:a phase II multicentre,randomized,double-blind,placebo-controlled trial[J].Diabetes Obes Metab,2013,15(5):432-440. [13]Bell KF,Katz A,Sheehan JJ.Quality measure attainment with dapagliflozin plus metformin extended-release as initial combination therapy in patients with type 2 diabetes:a post hoc pooled analysis of two clinical studies[J].Risk Manag Healthc Policy,2016,14(9):231-241. [14]Bailey CJ,Gross JL,Hennicken D,et al.Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin:a randomized,double-blind,placebo-controlled 102-week trial[J].BMC Med,2013,20(11):43. [15]Jabbour SA,Hardy E,Sugg J,et al.Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin:a 24-week,multicenter,randomized,double-blind,placebo-controlled study[J].Diabetes Care,2014,37(3):740-750. [16]Wilding JP,Woo V,Rohwedder K,et al.Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin:efficacy and safety over 2 years[J].Diabetes Obes Metab,2014,16(2):124-136. [17]Heerspink HJL,Zeeuw DD,Wie L,et al.Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes[J].Diabetes Obesity & Metabolism,2013,15(9):853-862. [18]Reed JW.Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure[J].Vase Health Risk Manag,2016(12):393-405. [19]Wilding JP,Woo V,Soler NG,et al.Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin[J].Dtsch Med Wochenschr,2013,138(1):S27-S38. [20]Strojek K,Yoon KH,Hruba V,et al.Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride[J].Dtsch Med Wochenschr,2013,138(1):S16-S26.
相似文献/References:
[1]黄德斌,章臻翊,章 婷,等.2型糖尿病患者亚临床甲状腺功能减退与白蛋白尿的关系研究[J].医学信息,2018,31(02):88.[doi:10.3969/j.issn.1006-1959.2018.02.030]
HUANG De-bin,ZHANG Zhen-yi,ZHANG Ting,et al.Relationship between Subclinical Hypothyroidism and Albuminuria in
Patients with Type 2 Diabetes Mellitus[J].Medical Information,2018,31(19):88.[doi:10.3969/j.issn.1006-1959.2018.02.030]
[2]邓婷婷,王亚洲,张 红.口福怡稻治疗2型糖尿病的临床效果研究[J].医学信息,2018,31(03):116.[doi:10.3969/j.issn.1006-1959.2018.03.039]
DENG Ting-ting,WANG Ya-zhou,ZHANG Hong.Clinical Study on the Treatment of Type 2 Diabetes Mellitus with Kou Fuyi Dao[J].Medical Information,2018,31(19):116.[doi:10.3969/j.issn.1006-1959.2018.03.039]
[3]曹岚,侯瑞田,王福慧,等.Lp-PLA2血小板相关因子与2型糖尿病合并高血压病的
相关性研究[J].医学信息,2018,31(05):3.[doi:10.3969/j.issn.1006-1959.2018.05.002]
CAO Lan,HOU Rui-tian,WANG Fu-hui,et al.Study on the Correlation between Lp-PLA2 Platelet-associated Factors and Type 2 Diabetes Mellitus Complicated with Hypertension[J].Medical Information,2018,31(19):3.[doi:10.3969/j.issn.1006-1959.2018.05.002]
[4]靳雪芹,邓正聪.代谢综合征与肿瘤关系的研究进展[J].医学信息,2018,31(05):35.[doi:10.3969/j.issn.1006-1959.2018.05.014]
JIN Xue-qin,DENG Zheng-cong.Research Progress on the Relationship between Metabolic Syndrome and Tumor[J].Medical Information,2018,31(19):35.[doi:10.3969/j.issn.1006-1959.2018.05.014]
[5]刘 洪.地特胰岛素或甘精胰岛素联合使用口服药物治疗2型糖尿病疗效及对体重的影响分析[J].医学信息,2018,31(09):135.[doi:10.3969/j.issn.1006-1959.2018.09.042]
LIU Hong.Effect of Insulin Detemir or Insulin Glargine Combined with Oral Medication on Type 2 Diabetes Mellitus and its Influence on Body Weight[J].Medical Information,2018,31(19):135.[doi:10.3969/j.issn.1006-1959.2018.09.042]
[6]郭云飞,王亚柱,刘 超,等.血浆致动脉硬化指数与冠心病合并2型糖尿病的相关性分析[J].医学信息,2022,35(09):108.[doi:10.3969/j.issn.1006-1959.2022.09.027]
GUO Yun-fei,WANG Ya-zhu,LIU Chao,et al.Correlation Between Plasma Arteriosclerosis Index and Coronary Heart Disease Complicated with Type 2 Diabetes Mellitus[J].Medical Information,2022,35(19):108.[doi:10.3969/j.issn.1006-1959.2022.09.027]
[7]余 佳.早期胰岛素强化治疗对初诊2型糖尿病患者血糖控制效果及颈动脉粥样硬化进展的影响[J].医学信息,2022,35(10):140.[doi:10.3969/j.issn.1006-1959.2022.10.034]
YU Jia.Effect of Early Intensive Insulin Therapy on Blood Glucose Control and Progression of Carotid Atherosclerosis in Newly Diagnosed Type 2 Diabetic Mellitus Patients[J].Medical Information,2022,35(19):140.[doi:10.3969/j.issn.1006-1959.2022.10.034]
[8]张剑君.2型糖尿病参与血管衰老的机制[J].医学信息,2022,35(11):37.[doi:10.3969/j.issn.1006-1959.2022.11.011]
ZHANG Jian-jun.The Mechanism of Type 2 Diabetes Mellitus in Vascular Aging[J].Medical Information,2022,35(19):37.[doi:10.3969/j.issn.1006-1959.2022.11.011]
[9]刘静波,黄 萍,赵 静.应用微信平台对初发中青年2型糖尿病患者进行
健康管理模式的研究[J].医学信息,2018,31(14):98.[doi:10.3969/j.issn.1006-1959.2018.14.028]
LIU Jing-bo,HUANG Ping,ZHAO Jing.Study on the Health Management Model of Young and Middle-aged Patients with Type 2 Diabetes Mellitus by WeChat Platform[J].Medical Information,2018,31(19):98.[doi:10.3969/j.issn.1006-1959.2018.14.028]
[10]丁 星,赵 畅,张海严,等.麦邦数据远程传输型血糖仪临床测量准确性的评价研究[J].医学信息,2018,31(15):64.[doi:10.3969/j.issn.1006-1959.2018.15.020]
DING Xing,ZHAO Chang,ZHANG Hai-yan,et al.Evaluation of Accuracy of Clinical Measurement of Maibang Remote Data Transmission Glucometer[J].Medical Information,2018,31(19):64.[doi:10.3969/j.issn.1006-1959.2018.15.020]
[11]董 健.达格列净治疗2型糖尿病的疗效及其对体质指数的影响[J].医学信息,2020,33(07):158.[doi:10.3969/j.issn.1006-1959.2020.07.052]
DONG Jian.The Therapeutic Effect of Dapagliflozin on Type 2 Diabetes and Its Influence on Body Mass Index[J].Medical Information,2020,33(19):158.[doi:10.3969/j.issn.1006-1959.2020.07.052]
[12]徐晨曦.达格列净联合DPP-4抑制剂与二甲双胍对血糖控制不佳2型糖尿病患者血糖及脂代谢的影响[J].医学信息,2022,35(09):165.[doi:10.3969/j.issn.1006-1959.2022.09.042]
XU Chen-xi.Effects of Daglitazone Combined with DPP-4 Inhibitor and Metformin on Blood Glucose and Lipid Metabolism in Patients with Type 2 Diabetes Mellitus with Poor Glycemic Control[J].Medical Information,2022,35(19):165.[doi:10.3969/j.issn.1006-1959.2022.09.042]